<DOC>
	<DOCNO>NCT01022255</DOCNO>
	<brief_summary>This phase I study evaluate safety tolerability autologous idiotype vaccine manufacture magnICON technology patient relapse follicular lymphoma complete partial remission follow non-antiCD20 contain salvage therapy . Data term idiotype-specific immune response also obtain .</brief_summary>
	<brief_title>Autologous Vaccine Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects histologically prove follicular lymphoma ( grade 1 , 2 , 3a ) , clinical relapse/progression require treatment Subjects must first line treatment consist rituximab without rituximab maintenance therapy ( i.e . rituximab monotherapy , RCHOP , RCVP , RFND , etc ) At least 4 month since last rituximab exposure Subjects may number prior treatment regimen . If enrol transform follicular lymphoma , study subject must anthracycline previous regimen Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy least 12 month Presence least 2x2 cm diameter lymph node ( either single lymph node combine volume lymphoid tissue ) accessible excision ; histological confirmation diagnosis manufacture vaccine Measurable disease neck , chest , abdomen , pelvis assess compute tomography ( CT ) scan response 2nd line chemotherapy define criterion Cheson et al ( JCO 2007 ; 25:579 , see appendix 15.2 ref 65 ) . PET scan result require enrollment Exposure rituximab antiCD20 direct therapy within 4 month prior enrollment History human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection Active clinically serious infection ( &gt; grade 2 National Cancer Institute Common Toxic Criteria [ NCICTC ] version 3.0 ) Symptomatic metastatic brain meningeal tumor include lymphoma unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry History organ allograft Patients undergoing renal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>autologous vaccine</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>magnICON</keyword>
	<keyword>plant-made vaccine</keyword>
	<keyword>immune response</keyword>
</DOC>